Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01195662
Registration number
NCT01195662
Ethics application status
Date submitted
3/09/2010
Date registered
6/09/2010
Date last updated
29/12/2016
Titles & IDs
Public title
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
Query!
Scientific title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) and an Additional Antihypertensive Medication
Query!
Secondary ID [1]
0
0
2010-019798-13
Query!
Secondary ID [2]
0
0
MB102-077 ST
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Type 2 Diabetes
0
0
Query!
Condition category
Condition code
Cardiovascular
0
0
0
0
Query!
Hypertension
Query!
Metabolic and Endocrine
0
0
0
0
Query!
Diabetes
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Dapagliflozin
Treatment: Drugs - Placebo matching Dapagliflozin
Experimental: Dapagliflozin 10 mg - Dapagliflozin 10 mg tablets
Placebo Comparator: Placebo matching Dapagliflozin - Placebo tablets matching dapagliflozin tablets
Treatment: Drugs: Dapagliflozin
Tablets, Oral, 10 mg, once daily, Up to 12 weeks
Treatment: Drugs: Placebo matching Dapagliflozin
Tablets, Oral, 0 mg, once daily, Up to 12 weeks
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Adjusted Mean Change From Baseline in Seated Systolic Blood Pressure for 12 Week Double-Blind Treatment Period - Randomized Participants
Query!
Assessment method [1]
0
0
Systolic blood pressure (SBP) was measured in millimeters of mercury (mmHg) on Day -1, Day 1, Weeks 2, 4, 8, and 12 of the Double Blind Period. Blood pressure (BP) values were obtained after the participant was seated for quietly for 10 minutes; a mean of 3 replicate measurements was taken at least 1 minute apart. However, if the 3 consecutive seated BP readings were not within 8 mm Hg of each other, an additional 2 BP readings were obtained (total = 5) and incorporated into the calculated mean. BP was measured in both arms. If the BP was higher in one arm than the other, then this arm was used; if no difference, the participant's dominant arm was used for all future BP measurements. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. Participants refrained from ingestion of caffeine, alcohol, or nicotine at least 10 hours prior to their visit and having their BP measured.
Query!
Timepoint [1]
0
0
Baseline to Week 12
Query!
Primary outcome [2]
0
0
Adjusted Mean Change From Baseline in Hemoglobin A1c (HbA1c) for 12 Week Double-Blind Treatment Period - Randomized Participants
Query!
Assessment method [2]
0
0
Adjusted mean change in glycosylated hemoglobin ( HbA1c) from baseline at Week 12 was calculated. HbA1c was measured as percent of hemoglobin by a central laboratory. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. HbA1c values were obtained at enrollment and lead-in (Day -28) periods, and at Day 1, Weeks 4, 8, and 12, in the double-blind period.
Query!
Timepoint [2]
0
0
Baseline to Week 12
Query!
Secondary outcome [1]
0
0
Adjusted Mean Change From Baseline in 24-hour Ambulatory Systolic Blood Pressure at Week 12 Last Observation Carried Forward (LOCF)
Query!
Assessment method [1]
0
0
Ambulatory 24 hour (hr) blood pressure monitoring (ABPM) was performed at baseline, which was during the lead-in period (between Day -7 and Day -1 prior to randomization) and 1 week prior to the Week 12 visit/end of treatment visit. If no Week 12 measurement was available, the last available earlier post-baseline measurement was used (LOCF) for analysis. Initiation of the 24-hr ABPM began between 6am and 11am to ensure trough BP measurements were obtained.The ABPM units were calibrated, and used per the manufacturer's and central ABPM vendor instructions. BP was measured in mmHg. Participants had to have a mean 24-hour ABPM = 130/80 mmHg prior to randomization. All medication was withheld on the morning of the study visit and brought to the visit site by the participant. Once the ABPM cuff was in place, all morning medication was taken while at the site.
Query!
Timepoint [1]
0
0
Baseline, Week 12
Query!
Secondary outcome [2]
0
0
Adjusted Mean Change From Baseline in Seated Diastolic Blood Pressure (DBP) for 12 Week Double-Blind Treatment Period - Randomized Participants
Query!
Assessment method [2]
0
0
Diastolic BP was measured in millimeters of mercury (mmHg) on Day -1, Day 1, Weeks 2, 4, 8, and 12 of the Double Blind Period. Diastolic BP values were obtained after the participant was seated for quietly for 10 minutes; a mean of 3 replicate measurements was taken at least 1 minute apart. However, if the 3 consecutive seated BP readings were not within 8 mm Hg of each other, an additional 2 BP readings were obtained (total = 5) and incorporated into the calculated mean. BP was measured in both arms. If the pressure was higher in one arm than the other, then this arm was used; if no difference, the participant's dominant arm was used for all future BP measurements. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. Participants refrained from ingestion of caffeine, alcohol, or nicotine at least 10 hours prior to their visit and having their BP measured.
Query!
Timepoint [2]
0
0
Baseline to Week 12
Query!
Secondary outcome [3]
0
0
Adjusted Mean Change From Baseline in 24-hr Ambulatory Diastolic Blood Pressure at Week 12 (LOCF)
Query!
Assessment method [3]
0
0
Ambulatory 24 hour (hr) BP monitoring (ABPM) was performed at baseline, which was during the lead-in period (between Day -7 and Day -1 prior to randomization) and 1 week prior to the Week 12 visit/end of treatment visit. If no Week 12 measurement was available, the last available earlier post-baseline measurement was used (LOCF). Initiation of the 24-hr ABPM began between 6am and 11am to ensure trough BP measurements were obtained. The ABPM units were calibrated, and used per the manufacturer's and central ABPM vendor instructions. BP was measured in mmHg. Participants had to have a mean 24-hour ABPM = 130/80 mmHg prior to randomization. All medication was withheld on the morning of the study visit and brought to the visit site by the participant. Once the ABPM cuff was in place, all morning medication was taken while at the site.
Query!
Timepoint [3]
0
0
Baseline, Week 12
Query!
Secondary outcome [4]
0
0
Adjusted Mean Change From Baseline in Serum Uric Acid at Week 12 in Double-Blind Treatment Period - Randomized Participants
Query!
Assessment method [4]
0
0
Adjusted mean change in serum uric acid from baseline at Week 12 was calculated. Serum uric acid was measured in milligrams per deciliter (mg/dL) by a central laboratory. Baseline was defined as the last assessment prior to the start date and time of the first dose of the double-blind study medication. Serum uric acid measurements were obtained at qualification and lead-in (Day -28) periods, and at Day 1, Weeks 4, 8, and 12, in the double-blind period but only the change from baseline at Week 12 was considered a secondary endpoint and is presented.
Query!
Timepoint [4]
0
0
Baseline, Week 12
Query!
Secondary outcome [5]
0
0
Number of Participants With Deaths,Serious Adverse Events (SAEs), Adverse Events (AEs), Hypoglycemia Events, Discontinuation Due to AEs, SAEs and Hypoglycemia, During the 12 Week Double Blind Period, Including Data After Rescue
Query!
Assessment method [5]
0
0
Medical Dictionary for Regulatory Activities (MedDRA), version 15.1 AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Related=having certain, probable, possible, or missing relationship to study drug as per the investigator. Events captured from baseline to last double blind dose plus 4 days for AEs, plus 30 days for SAEs during the Double Blind 12 Week Period. Only hypoglycemia reported as an SAE is included in AE/SAE categories . All reported hypoglycemia events within 4 days of last day of treatment are included as hypoglycemic events.
Query!
Timepoint [5]
0
0
Baseline to last dose of 12 weeks of double blind medication plus 30 days if SAE or plus 4 days if AE/hypoglycemic event
Query!
Secondary outcome [6]
0
0
Number of Participants With Marked Chemistry Laboratory Abnormalities in 12 Week Double Blind Treatment Period, Including Data After Rescue
Query!
Assessment method [6]
0
0
Samples obtained: Day 1, Weeks 4, 8,12 in Double Blind Period. Baseline: last assessment prior to start of first dose of double-blind treatment. Pretreatment (PreRX); grams per deciliter (g/dL); upper limit of normal (ULN); milliequivalent per liter (mEq/L); greater than (>) less than (<); Units per liter (U/L), Marked abnormality Low (High): hemoglobin <6 (>18 females or >20 males) g/dL; creatinine (>=1.5*preRX, >=2.5 mg/dL); glucose < 54 or (> 350) mg/dL; albumin <= 2 or (> 6) g/dL; creatine kinase >5*ULN; albumin/creatinine ratio (>1800 mg/G); calcium <7.5 (>1 and >0.5 from PreRX) mg/dL; bicarbonate <=13 meq/dL; potassium <=2.5 (>6) meq/L; magnesium <1 (>4) mEq/L; sodium < 130 mEq/L (>150 mEq/L; phosphorus (>=5.6 mg/dL age 17-65, >=5.1 is >=66 years); Albumin/creatinine ratio (>1800 mg/g). Note: Hepatic tests are presented separately in next outcome measure.
Query!
Timepoint [6]
0
0
Baseline (Day 1) to last dose double blind medication (Week 12) plus 4 days
Query!
Secondary outcome [7]
0
0
Number of Participants With Elevated Liver Laboratory Tests in Participants Treated With Double Blind 10 mg Dapagliflozin or Placebo , Including Data After Rescue
Query!
Assessment method [7]
0
0
Laboratories were obtained at Day 1, Weeks 4, 8 and 12 in the Double Blind Period. Baseline: last assessment prior to start of first dose of double-blind treatment. Includes laboratory values measured after the first date of double-blind treatment and up to and including the last day of double blind treatment plus 30 days. Upper limit of normal (ULN);, alanine aminotransferase (ALT); aspartate aminotransferase (AST); alkaline phosphatase (ALP). Marked abnormality (High): AST and ALT (>3*ULN); ALP (>1.5*ULN); bilirubin (>1.5*ULN). Participants with abnormally elevated liver laboratory tests were followed 30 days after the last dose of study drug.
Query!
Timepoint [7]
0
0
Baseline (Day 1) to last dose double blind medication (Week 12) Plus 30 days
Query!
Secondary outcome [8]
0
0
Number of Participants With Normal or Abnormal Electrocardiogram Summary Tracing at Week 12 (LOCF), Including Data After Rescue
Query!
Assessment method [8]
0
0
12-Lead electrocardiograms (ECGs) were performed at Enrollment, Day 1 of Double Blind Period and Week 12/End of treatment visit (last observation carried forward) on participants who were supine. ECGs were assessed by the investigator as normal or abnormal. Baseline (BL) was Day 1 prior to dosing or last observation prior to dosing.
Query!
Timepoint [8]
0
0
Baseline, Week 12
Query!
Secondary outcome [9]
0
0
Proportion of Participants With Orthostatic Hypotension at Baseline and Week 12, Including Data After Rescue
Query!
Assessment method [9]
0
0
Orthostatic hypotension was defined as a decrease from supine to standing of > 20 mmHg in systolic BP or >10 mmHg in diastolic BP. Proportion was calculated from number of participants with orthostatic hypotension (n) divided by the number of treated participants (N). n/N presented as a percent (%). Baseline was Day 1 of the double blind Period. Measurements for orthostatic hypotension were taken on Day 1 and at Week 12 visit and does not reflect AEs reported by the investigator.
Query!
Timepoint [9]
0
0
Baseline (Day 1), Week 12
Query!
Eligibility
Key inclusion criteria
- Written informed consent
- Males and females, 18 to 89 years old, with type 2 diabetes with inadequate glycemic
control HbA1c between 7-10.5% and uncontrolled hypertension Systolic Blood Pressure
(SBP) 140-165 and Diastolic Blood Pressure (DBP) 85-105
- Subjects must have a mean 24 hr blood pressure = 130/80 determined by Ambulatory Blood
Pressure Monitoring (ABPM) within 1 week prior to Day 1 visit
- Stable dose of oral antidiabetic agent (OAD) for at least 6 weeks [12 wks for
Thiazolidinedione (TZD)] or a stable daily dose of insulin, as a monotherapy or in
combination with another OAD, for 8 weeks, and a stable dose of ACEI or ARB and 1
additional antihypertensive medication for at least 4 weeks
- C-peptide = 0.8 ng/mL
- Body Mass Index = 45.0 kg/m2
- Serum creatinine < 1.50 mg/dL for men or < 1.40 mg/dL for women
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
89
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Aspartate aminotransferase (AST) and /or Alanine aminotransferase (ALT) > 3.0*upper
limit of normal (ULN)
- Serum total bilirubin = 1.5*ULN
- Creatinine kinase > 3*ULN
- Symptoms of severely uncontrolled diabetes
- History of malignant or accelerated hypertension
- Currently unstable or serious cardiovascular, renal, hepatic, hematological,
oncological, endocrine, psychiatric, or rheumatic diseases
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/10/2010
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/02/2013
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
2245
Query!
Recruitment in Australia
Recruitment state(s)
NSW,VIC,WA
Query!
Recruitment hospital [1]
0
0
Local Institution - Camperdown
Query!
Recruitment hospital [2]
0
0
Local Institution - Heidelberg
Query!
Recruitment hospital [3]
0
0
Local Institution - Nedlands
Query!
Recruitment postcode(s) [1]
0
0
2050 - Camperdown
Query!
Recruitment postcode(s) [2]
0
0
3081 - Heidelberg
Query!
Recruitment postcode(s) [3]
0
0
6009 - Nedlands
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Arkansas
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
California
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Connecticut
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Delaware
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Florida
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Georgia
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Illinois
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Indiana
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Louisiana
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Maine
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Maryland
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Massachusetts
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Michigan
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Mississippi
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Missouri
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Nevada
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
New Jersey
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
New York
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
North Carolina
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
North Dakota
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Ohio
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Oklahoma
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Oregon
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
Pennsylvania
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
Rhode Island
Query!
Country [28]
0
0
United States of America
Query!
State/province [28]
0
0
South Carolina
Query!
Country [29]
0
0
United States of America
Query!
State/province [29]
0
0
Tennessee
Query!
Country [30]
0
0
United States of America
Query!
State/province [30]
0
0
Texas
Query!
Country [31]
0
0
United States of America
Query!
State/province [31]
0
0
Utah
Query!
Country [32]
0
0
United States of America
Query!
State/province [32]
0
0
Virginia
Query!
Country [33]
0
0
United States of America
Query!
State/province [33]
0
0
Washington
Query!
Country [34]
0
0
United States of America
Query!
State/province [34]
0
0
Wisconsin
Query!
Country [35]
0
0
Canada
Query!
State/province [35]
0
0
British Columbia
Query!
Country [36]
0
0
Canada
Query!
State/province [36]
0
0
New Brunswick
Query!
Country [37]
0
0
Canada
Query!
State/province [37]
0
0
Ontario
Query!
Country [38]
0
0
Canada
Query!
State/province [38]
0
0
Quebec
Query!
Country [39]
0
0
Canada
Query!
State/province [39]
0
0
Saskatchewan
Query!
Country [40]
0
0
Colombia
Query!
State/province [40]
0
0
Quindio
Query!
Country [41]
0
0
Colombia
Query!
State/province [41]
0
0
Santander
Query!
Country [42]
0
0
Colombia
Query!
State/province [42]
0
0
Barranquilla
Query!
Country [43]
0
0
Colombia
Query!
State/province [43]
0
0
Bogota
Query!
Country [44]
0
0
Czech Republic
Query!
State/province [44]
0
0
Beroun
Query!
Country [45]
0
0
Czech Republic
Query!
State/province [45]
0
0
Cheb
Query!
Country [46]
0
0
Czech Republic
Query!
State/province [46]
0
0
Havirov
Query!
Country [47]
0
0
Czech Republic
Query!
State/province [47]
0
0
Krnov
Query!
Country [48]
0
0
Czech Republic
Query!
State/province [48]
0
0
Liberec
Query!
Country [49]
0
0
Czech Republic
Query!
State/province [49]
0
0
Ostrava
Query!
Country [50]
0
0
Czech Republic
Query!
State/province [50]
0
0
Prague 1
Query!
Country [51]
0
0
Czech Republic
Query!
State/province [51]
0
0
Praha 4
Query!
Country [52]
0
0
Denmark
Query!
State/province [52]
0
0
Copenhagen
Query!
Country [53]
0
0
Denmark
Query!
State/province [53]
0
0
Frederiksberg
Query!
Country [54]
0
0
Denmark
Query!
State/province [54]
0
0
Gentofte
Query!
Country [55]
0
0
Denmark
Query!
State/province [55]
0
0
Slagelse
Query!
Country [56]
0
0
Finland
Query!
State/province [56]
0
0
Helsinki
Query!
Country [57]
0
0
Finland
Query!
State/province [57]
0
0
Kerava
Query!
Country [58]
0
0
Finland
Query!
State/province [58]
0
0
Kokkola
Query!
Country [59]
0
0
Finland
Query!
State/province [59]
0
0
Oulu
Query!
Country [60]
0
0
Germany
Query!
State/province [60]
0
0
Bavaria
Query!
Country [61]
0
0
Germany
Query!
State/province [61]
0
0
Nordrhein-Westfalen
Query!
Country [62]
0
0
Germany
Query!
State/province [62]
0
0
Bad Kreuznach
Query!
Country [63]
0
0
Germany
Query!
State/province [63]
0
0
Berlin
Query!
Country [64]
0
0
Germany
Query!
State/province [64]
0
0
Dortmund
Query!
Country [65]
0
0
Germany
Query!
State/province [65]
0
0
Dresden
Query!
Country [66]
0
0
Germany
Query!
State/province [66]
0
0
Karlsruhe
Query!
Country [67]
0
0
Germany
Query!
State/province [67]
0
0
Kothen
Query!
Country [68]
0
0
Germany
Query!
State/province [68]
0
0
Kronshagen
Query!
Country [69]
0
0
Germany
Query!
State/province [69]
0
0
Langenfeld
Query!
Country [70]
0
0
Germany
Query!
State/province [70]
0
0
Lueneburg
Query!
Country [71]
0
0
Germany
Query!
State/province [71]
0
0
Magdeburg
Query!
Country [72]
0
0
Germany
Query!
State/province [72]
0
0
Mainz
Query!
Country [73]
0
0
Germany
Query!
State/province [73]
0
0
Mannheim
Query!
Country [74]
0
0
Germany
Query!
State/province [74]
0
0
Saarbruecken
Query!
Country [75]
0
0
Germany
Query!
State/province [75]
0
0
Wuestensachsen
Query!
Country [76]
0
0
Hungary
Query!
State/province [76]
0
0
Heves
Query!
Country [77]
0
0
Hungary
Query!
State/province [77]
0
0
Budapest
Query!
Country [78]
0
0
Hungary
Query!
State/province [78]
0
0
Eger
Query!
Country [79]
0
0
Hungary
Query!
State/province [79]
0
0
Kisvarda
Query!
Country [80]
0
0
Hungary
Query!
State/province [80]
0
0
Miskolc
Query!
Country [81]
0
0
Hungary
Query!
State/province [81]
0
0
Nyiregyhaza
Query!
Country [82]
0
0
Hungary
Query!
State/province [82]
0
0
Satoraljaujhely
Query!
Country [83]
0
0
Hungary
Query!
State/province [83]
0
0
Sopron
Query!
Country [84]
0
0
Hungary
Query!
State/province [84]
0
0
Szeged
Query!
Country [85]
0
0
Hungary
Query!
State/province [85]
0
0
Szekszard
Query!
Country [86]
0
0
India
Query!
State/province [86]
0
0
Andhra Pradesh
Query!
Country [87]
0
0
India
Query!
State/province [87]
0
0
Karnataka
Query!
Country [88]
0
0
India
Query!
State/province [88]
0
0
Karnatka
Query!
Country [89]
0
0
India
Query!
State/province [89]
0
0
Madhya Pradesh
Query!
Country [90]
0
0
India
Query!
State/province [90]
0
0
Maharashtra
Query!
Country [91]
0
0
India
Query!
State/province [91]
0
0
New Delhi
Query!
Country [92]
0
0
India
Query!
State/province [92]
0
0
Rajasthan
Query!
Country [93]
0
0
India
Query!
State/province [93]
0
0
Tamil Nadu
Query!
Country [94]
0
0
India
Query!
State/province [94]
0
0
Tamilnadu
Query!
Country [95]
0
0
India
Query!
State/province [95]
0
0
Chennai Tamilnadu
Query!
Country [96]
0
0
India
Query!
State/province [96]
0
0
Hyderabad
Query!
Country [97]
0
0
India
Query!
State/province [97]
0
0
Nagpur
Query!
Country [98]
0
0
India
Query!
State/province [98]
0
0
Trivandrum
Query!
Country [99]
0
0
Ireland
Query!
State/province [99]
0
0
Dublin
Query!
Country [100]
0
0
Ireland
Query!
State/province [100]
0
0
Galway
Query!
Country [101]
0
0
Mexico
Query!
State/province [101]
0
0
Coahuila
Query!
Country [102]
0
0
Mexico
Query!
State/province [102]
0
0
Distrito Federal
Query!
Country [103]
0
0
Mexico
Query!
State/province [103]
0
0
Jalisco
Query!
Country [104]
0
0
Mexico
Query!
State/province [104]
0
0
Morelos
Query!
Country [105]
0
0
Mexico
Query!
State/province [105]
0
0
Nuevo Leon
Query!
Country [106]
0
0
Mexico
Query!
State/province [106]
0
0
Sinaloa
Query!
Country [107]
0
0
Mexico
Query!
State/province [107]
0
0
Yucatan
Query!
Country [108]
0
0
Mexico
Query!
State/province [108]
0
0
Chihuahua
Query!
Country [109]
0
0
Mexico
Query!
State/province [109]
0
0
Del. Benito Juarez
Query!
Country [110]
0
0
Mexico
Query!
State/province [110]
0
0
Delegacion Tlalpan
Query!
Country [111]
0
0
Mexico
Query!
State/province [111]
0
0
San Luis Potosi
Query!
Country [112]
0
0
Poland
Query!
State/province [112]
0
0
Bialystok
Query!
Country [113]
0
0
Poland
Query!
State/province [113]
0
0
Chrzanow
Query!
Country [114]
0
0
Poland
Query!
State/province [114]
0
0
Elblag
Query!
Country [115]
0
0
Poland
Query!
State/province [115]
0
0
Gdansk
Query!
Country [116]
0
0
Poland
Query!
State/province [116]
0
0
Gdynia
Query!
Country [117]
0
0
Poland
Query!
State/province [117]
0
0
Kamieniec Zabkowicki
Query!
Country [118]
0
0
Poland
Query!
State/province [118]
0
0
Katowice
Query!
Country [119]
0
0
Poland
Query!
State/province [119]
0
0
Kielce
Query!
Country [120]
0
0
Poland
Query!
State/province [120]
0
0
Krakow
Query!
Country [121]
0
0
Poland
Query!
State/province [121]
0
0
Lodz
Query!
Country [122]
0
0
Poland
Query!
State/province [122]
0
0
Lublin
Query!
Country [123]
0
0
Poland
Query!
State/province [123]
0
0
Ostroda
Query!
Country [124]
0
0
Poland
Query!
State/province [124]
0
0
Poznan
Query!
Country [125]
0
0
Poland
Query!
State/province [125]
0
0
Warsaw
Query!
Country [126]
0
0
Poland
Query!
State/province [126]
0
0
Warszawa
Query!
Country [127]
0
0
Poland
Query!
State/province [127]
0
0
Wroclaw
Query!
Country [128]
0
0
Poland
Query!
State/province [128]
0
0
Zabrze
Query!
Country [129]
0
0
Puerto Rico
Query!
State/province [129]
0
0
Fajard
Query!
Country [130]
0
0
Puerto Rico
Query!
State/province [130]
0
0
Ponce
Query!
Country [131]
0
0
Puerto Rico
Query!
State/province [131]
0
0
San Juan
Query!
Country [132]
0
0
Romania
Query!
State/province [132]
0
0
Bihor
Query!
Country [133]
0
0
Romania
Query!
State/province [133]
0
0
Jud. Bihor
Query!
Country [134]
0
0
Romania
Query!
State/province [134]
0
0
Jud. Timis
Query!
Country [135]
0
0
Romania
Query!
State/province [135]
0
0
Mures
Query!
Country [136]
0
0
Romania
Query!
State/province [136]
0
0
Prahova
Query!
Country [137]
0
0
Romania
Query!
State/province [137]
0
0
Timis
Query!
Country [138]
0
0
Romania
Query!
State/province [138]
0
0
Bucuresti
Query!
Country [139]
0
0
Romania
Query!
State/province [139]
0
0
Cluj-Napoca
Query!
Country [140]
0
0
Romania
Query!
State/province [140]
0
0
Satu Mare
Query!
Country [141]
0
0
Romania
Query!
State/province [141]
0
0
Sibiu
Query!
Country [142]
0
0
United Kingdom
Query!
State/province [142]
0
0
Ayrshire
Query!
Country [143]
0
0
United Kingdom
Query!
State/province [143]
0
0
Cambridgeshire
Query!
Country [144]
0
0
United Kingdom
Query!
State/province [144]
0
0
West Midlands
Query!
Country [145]
0
0
United Kingdom
Query!
State/province [145]
0
0
Wiltshire
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
AstraZeneca
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/Industry
Query!
Name [1]
0
0
Bristol-Myers Squibb
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to learn if BMS-512148 (Dapagliflozin), after 12 weeks, can
improve (decrease) blood pressure in patients with type 2 diabetes with uncontrolled
hypertension who are on an Angiotensin-converting enzyme inhibitor (ACEI) or an Angiotensin
Receptor Blocker (ARB).The safety of this treatment will also be studied
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01195662
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Bristol-Myers Squibb
Query!
Address
0
0
Bristol-Myers Squibb
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01195662
Download to PDF